{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:45:27Z","timestamp":1792449927103,"version":"4.5.0"},"reference-count":204,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19AI133127"],"award-info":[{"award-number":["U19AI133127"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21\/R33AI094519"],"award-info":[{"award-number":["R21\/R33AI094519"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK107806"],"award-info":[{"award-number":["R01DK107806"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Johns Hopkins University Center for AIDS Research","award":["P30AI094189"],"award-info":[{"award-number":["P30AI094189"]}]},{"name":"2015 Burroughs Wellcome Fund Preterm Birth Initiative","award":["1015020"],"award-info":[{"award-number":["1015020"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.jconrel.2016.06.016","type":"journal-article","created":{"date-parts":[[2016,6,12]],"date-time":"2016-06-12T03:03:00Z","timestamp":1465700580000},"page":"504-526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":509,"special_numbering":"C","title":["Nanoparticles for oral delivery: Design, evaluation and state-of-the-art"],"prefix":"10.1016","volume":"240","author":[{"given":"Abhijit A.","family":"Date","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Ensign","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2016.06.016_bb0015","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","article-title":"Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers","volume":"64","author":"Ensign","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0020","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1517\/17425247.2015.1018175","article-title":"Polymeric nanoparticle drug delivery technologies for oral delivery applications","volume":"12","author":"Pridgen","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2016.06.016_bb0025","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.nano.2012.07.005","article-title":"Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective","volume":"8","author":"Hunter","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0030","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2014.09.031","article-title":"Targeting of gastrointestinal tract for amended delivery of protein\/peptide therapeutics: strategies and industrial perspectives","volume":"196","author":"Pawar","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1010635000879","article-title":"Oral delivery of taxanes","volume":"19","author":"Malingr\u00e9","year":"2001","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0040","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1517\/17425240902802861","article-title":"The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis","volume":"6","author":"Thornton","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0045","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1128\/AAC.01172-09","article-title":"Fasting increases tobramycin oral absorption in mice","volume":"54","author":"De Leo","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0050","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11095-012-0889-z","article-title":"Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs","volume":"30","author":"Gao","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0055","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1517\/17425247.2014.917077","article-title":"Oral peptide and protein delivery: intestinal obstacles and commercial prospects","volume":"11","author":"Smart","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0060","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijpharm.2013.02.030","article-title":"Approaches for enhancing oral bioavailability of peptides and proteins","volume":"447","author":"Renukuntla","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0065","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.biotechadv.2014.07.006","article-title":"A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules","volume":"32","author":"Choonara","year":"2014","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0070","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2217\/nnm.09.110","article-title":"Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery","volume":"5","author":"Roger","year":"2010","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0075","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.addr.2012.10.007","article-title":"Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery","volume":"65","author":"Yun","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2006.08.013","article-title":"Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach","volume":"116","author":"Rieux","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2005.10.031","article-title":"Gastroretentive dosage forms: overview and special case of Helicobacter pylori","volume":"111","author":"Bardonnet","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0090","doi-asserted-by":"crossref","first-page":"741","DOI":"10.4155\/tde.15.35","article-title":"Modification of drug delivery to improve antibiotic targeting to the stomach","volume":"6","author":"Adebisi","year":"2015","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0095","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2008.09.008","article-title":"Barrier properties of mucus","volume":"61","author":"Cone","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0100","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3109\/02652048.2011.590613","article-title":"Gastroretentive microparticles for drug delivery applications","volume":"28","author":"Adebisi","year":"2011","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0105","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.suc.2005.05.009","article-title":"Anatomy and physiology of the stomach","volume":"85","author":"Soybel","year":"2005","journal-title":"Surg. Clin. North Am."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0110","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/0192623313518113","article-title":"Comparative anatomy, physiology, and mechanisms of disease production of the esophagus, stomach, and small intestine","volume":"42","author":"Gelberg","year":"2014","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0115","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1111\/j.1750-3841.2008.00766.x","article-title":"Disintegration of solid foods in human stomach","volume":"73","author":"Kong","year":"2008","journal-title":"J. Food Sci."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0120","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1517\/17425247.2013.821978","article-title":"pH- and ion-sensitive polymers for drug delivery","volume":"10","author":"Yoshida","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0125","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/39.1.5","article-title":"The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection","volume":"39","author":"Erah","year":"1997","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0130","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","article-title":"Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues","volume":"61","author":"Lai","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0135","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.addr.2008.09.012","article-title":"Micro- and macrorheology of mucus","volume":"61","author":"Lai","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0140","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2008.09.008","article-title":"Barrier properties of mucus","volume":"61","author":"Cone","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0145","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2014011104","article-title":"Gastroretentive drug delivery systems for therapeutic management of peptic ulcer","volume":"31","author":"Garg","year":"2014","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0150","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jconrel.2013.02.028","article-title":"Raft forming system-an upcoming approach of gastroretentive drug delivery system","volume":"168","author":"Prajapati","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0155","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1046\/j.1523-5378.2003.00156.x","article-title":"Gastric juice, gastric tissue and blood antibiotic concentrations following omeprazole, amoxicillin and clarithromycin triple therapy","volume":"8","author":"Nakamura","year":"2003","journal-title":"Helicobacter"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0160","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/00004836-200608000-00011","article-title":"Clinical trial evaluating amoxicillin and clarithromycin hydrogels (Chitosan-polyacrylic acid polyionic complex) for H. pylori eradication","volume":"40","author":"Gisbert","year":"2006","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0165","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejpb.2012.07.014","article-title":"pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide\/protein drugs and poorly water-soluble drugs","volume":"82","author":"Wang","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0170","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1517\/17425247.2013.736962","article-title":"Eudragit: a technology evaluation","volume":"10","author":"Thakral","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0175","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.addr.2013.04.006","article-title":"Oral delivery of proteins by biodegradable nanoparticles","volume":"65","author":"Bakhru","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0180","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jconrel.2014.10.026","article-title":"Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse","volume":"197","author":"Maisel","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0185","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejpb.2013.12.012","article-title":"Development and in vivo evaluation of papain-functionalized nanoparticles","volume":"87","author":"M\u00fcller","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0190","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ejpb.2015.02.029","article-title":"The effect of nanoparticle permeation on the bulk rheological properties of mucus from the small intestine","volume":"96","author":"Wilcox","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0195","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejpb.2015.01.008","article-title":"Nanoparticles decorated with proteolytic enzymes, a promising strategy to overcome the mucus barrier","volume":"97","author":"Pereira de Sousa","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0200","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2015.01.004","article-title":"Mucus permeating thiomer nanoparticles","volume":"97","author":"K\u00f6llner","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0205","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1021\/bp0342553","article-title":"Transport of polymeric nanoparticle gene carriers in gastric mucus","volume":"20","author":"Dawson","year":"2004","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0210","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1073\/pnas.0608611104","article-title":"Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus","volume":"104","author":"Lai","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0215","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1021\/mp400087y","article-title":"Ex vivo characterization of particle transport in mucus secretions coating freshly excised mucosal tissues","volume":"10","author":"Ensign","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0220","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3109\/1061186X.2015.1086359","article-title":"Size selectivity of intestinal mucus to diffusing particulates is dependent on surface chemistry and exposure to lipids","volume":"23","author":"Yildiz","year":"2015","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0225","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejpb.2015.01.023","article-title":"Nanoparticle diffusion within intestinal mucus: three-dimensional response analysis dissecting the impact of particle surface charge, size and heterogeneity across polyelectrolyte, pegylated and viral particles","volume":"97","author":"Abdulkarim","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0230","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ijpharm.2016.01.022","article-title":"Insulin loaded mucus permeating nanoparticles: addressing the surface characteristics as feature to improve mucus permeation","volume":"500","author":"Pereira de Sousa","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0235","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1517\/17425247.2011.539200","article-title":"Vitamin B12 in drug delivery: breaking through the barriers to a B12 bioconjugate pharmaceutical","volume":"8","author":"Clardy","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0240","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.4155\/tde.11.129","article-title":"Intestinal receptor targeting for peptide delivery: an expert's personal perspective on reasons for failure and new opportunities","volume":"2","author":"Russell-Jones","year":"2011","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0245","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1002\/smll.201202623","article-title":"Nanoparticle transport in epithelial cells: pathway switching through bioconjugation","volume":"9","author":"Fowler","year":"2013","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0250","doi-asserted-by":"crossref","first-page":"213ra167","DOI":"10.1126\/scitranslmed.3007049","article-title":"Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery","volume":"5","author":"Pridgen","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0255","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jconrel.2012.02.006","article-title":"Crossing the barrier: targeting epithelial receptors for enhanced oral vaccine delivery","volume":"160","author":"Devriendt","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0260","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.4161\/hv.36174","article-title":"Roles of M cells in infection and mucosal vaccines","volume":"10","author":"Wang","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2006.08.013","article-title":"Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach","volume":"116","author":"Rieux","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0270","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.addr.2003.10.018","article-title":"M cell targeting by lectins: a strategy for mucosal vaccination and drug delivery","volume":"56","author":"Jepson","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0275","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.addr.2003.10.015","article-title":"The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery","volume":"56","author":"Gabor","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0280","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000200402","article-title":"Relationship between survival and binding of plant lectins during small intestinal passage and their effectiveness as growth factors","volume":"46","author":"Pusztai","year":"1990","journal-title":"Digestion"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0285","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v18.i4.10","article-title":"Targeted delivery of drugs to the gastrointestinal tract","volume":"18","author":"Lavelle","year":"2001","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0290","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1023\/A:1025061317400","article-title":"Toward targeted oral vaccine delivery systems: selection of lectin mimetics from combinatorial libraries","volume":"20","author":"Lambkin","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0295","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1021\/bm301222f","article-title":"Mucin multilayers assembled through sugar-lectin interactions","volume":"13","author":"Crouzier","year":"2012","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0300","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijpharm.2014.04.070","article-title":"Lectin-conjugated microspheres for eradication of Helicobacter pylori infection and interaction with mucus","volume":"470","author":"Adebisi","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0305","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejpb.2009.04.009","article-title":"Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination","volume":"73","author":"Fievez","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0310","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1097\/01.LAB.0000078741.55670.6E","article-title":"Characteristics of claudin expression in follicle-associated epithelium of Peyer's patches: preferential localization of claudin-4 at the apex of the dome region","volume":"83","author":"Tamagawa","year":"2003","journal-title":"Lab. Investig."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0315","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jconrel.2009.10.033","article-title":"Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery","volume":"142","author":"Rajapaksa","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0320","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jbiotec.2008.01.021","article-title":"Identification of a peptide sequence that improves transport of macromolecules across the intestinal mucosal barrier targeting goblet cells","volume":"135","author":"Kang","year":"2008","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0325","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0169-409X(01)00151-X","article-title":"Intestinal lymphatic drug transport: an update","volume":"50","author":"Porter","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0330","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.addr.2007.09.007","article-title":"Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update","volume":"60","author":"Trevaskis","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0335","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.addr.2011.05.017","article-title":"Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles","volume":"63","author":"Cai","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0340","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3109\/1061186X.2014.950664","article-title":"Recent approaches of lipid-based delivery system for lymphatic targeting via oral route","volume":"22","author":"Chaudhary","year":"2014","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0345","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/17425247.2014.866088","article-title":"Lymphatic system: a prospective area for advanced targeting of particulate drug carriers","volume":"11","author":"Singh","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0350","first-page":"2733","article-title":"Advanced drug delivery to the lymphatic system: lipid-based nanoformulations","volume":"8","author":"Khan","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0355","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nrd4608","article-title":"From sewer to saviour-targeting the lymphatic system to promote drug exposure and activity","volume":"14","author":"Trevaskis","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0360","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1742-4690-4-87","article-title":"Compartmentalization of the gut viral reservoir in HIV-1 infected patients","volume":"4","author":"van Marle","year":"2007","journal-title":"Retrovirology"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2013.12.031","article-title":"Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies","volume":"177","author":"Han","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0370","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jconrel.2012.01.028","article-title":"Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa","volume":"161","author":"Collnot","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0375","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1517\/17425247.2013.800480","article-title":"New targeting strategies in drug therapy of inflammatory bowel disease: mechanistic approaches and opportunities","volume":"10","author":"Wolk","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0380","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v28.i5.10","article-title":"Bacteria and pH-sensitive polysaccharide-polymer films for colon targeted delivery","volume":"28","author":"Esseku","year":"2011","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0385","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v24.i2.20","article-title":"Therapeutic opportunities in colon-specific drug-delivery systems","volume":"24","author":"Patel","year":"2007","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0390","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0928-0987(02)00221-X","article-title":"Microbially triggered drug delivery to the colon","volume":"18","author":"Sinha","year":"2003","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0395","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.nano.2015.02.018","article-title":"Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue","volume":"11","author":"Hua","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0400","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1073\/pnas.1006451107","article-title":"The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions","volume":"108","author":"Johansson","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0405","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/gutjnl-2012-303207","article-title":"Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis","volume":"63","author":"Johansson","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0410","doi-asserted-by":"crossref","first-page":"164","DOI":"10.15252\/embr.201439263","article-title":"The composition of the gut microbiota shapes the colon mucus barrier","volume":"16","author":"Jakobsson","year":"2015","journal-title":"EMBO Rep."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0415","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1023\/B:PHAM.0000019298.29561.cd","article-title":"Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes","volume":"21","author":"Jubeh","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0420","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1023\/A:1011032328064","article-title":"Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa","volume":"18","author":"Lamprecht","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0425","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1517\/17425247.2016.1114604","article-title":"Size-dependent nanoparticulate drug delivery in inflammatory bowel diseases","volume":"13","author":"Youshia","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0430","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1007\/BF02093613","article-title":"Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease","volume":"41","author":"Lih-Brody","year":"1996","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0435","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1136\/gut.34.9.1191","article-title":"Increased production of luminol enhanced chemiluminescence by the inflamed colonic mucosa in patients with ulcerative colitis","volume":"34","author":"Sedghi","year":"1993","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0440","article-title":"Polysaccharide-based micro\/nanocarriers for oral colon-targeted drug delivery","volume":"1-11","author":"Zhang","year":"2016","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0445","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1021\/js9702630","article-title":"Use of azo polymers for colon-specific drug delivery","volume":"86","author":"Van den Mooter","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0450","doi-asserted-by":"crossref","first-page":"5786","DOI":"10.3390\/nu6125786","article-title":"Dysbiotic events in gut microbiota: impact on human health","volume":"6","author":"Schippa","year":"2014","journal-title":"Nutrients"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1242\/dmm.017400","article-title":"How informative is the mouse for human gut microbiota research?","volume":"8","author":"Nguyen","year":"2015","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0460","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijpharm.2008.09.058","article-title":"Poly(ethylene glycol)-mesalazine conjugate for colon specific delivery","volume":"368","author":"Canevari","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0465","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.2042-7158.2011.01289.x","article-title":"Investigation into drug release from colon-specific azoreductase-activated steroid prodrugs using in-vitro models","volume":"63","author":"Ruiz","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0470","first-page":"15","article-title":"Reduction of beta-glucuronidase and nitroreductase activity by yoghurt in a murine colon cancer model","volume":"29","author":"de Moreno de LeBlanc","year":"2005","journal-title":"Biocell"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0475","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/08910600600733264","article-title":"\u03b2-Glucuronidase activity in germ-free, monoassociated and conventional mice","volume":"18","author":"Cardon","year":"2006","journal-title":"Microb. Ecol. Health Dis."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0480","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.addr.2003.10.017","article-title":"Drug targeting to the colon with lectins and neoglycoconjugates","volume":"56","author":"Minko","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0485","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jconrel.2014.05.046","article-title":"Lectin-decorated nanoparticles enhance binding to the inflamed tissue in experimental colitis","volume":"188","author":"Moulari","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0490","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.addr.2013.01.003","article-title":"In vitro and in vivo models for the study of oral delivery of nanoparticles","volume":"65","author":"Gamboa","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0495","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/138920013804545133","article-title":"Improving oral absorption via drug-loaded nanocarriers: absorption mechanisms, intestinal models and rational fabrication","volume":"14","author":"Shahbazi","year":"2013","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0500","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3109\/17435390.2014.948091","article-title":"Utility of models of the gastrointestinal tract for assessment of the digestion and absorption of engineered nanomaterials released from food matrices","volume":"9","author":"Lefebvre","year":"2015","journal-title":"Nanotoxicology"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0505","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1752-153X-8-46","article-title":"Nanotechnology in drug delivery: the need for more cell culture based studies in screening","volume":"8","author":"Kura","year":"2014","journal-title":"Chem. Cent. J."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0510","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0016-5085(89)80072-1","article-title":"Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability","volume":"96","author":"Hidalgo","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0515","series-title":"Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability","first-page":"90","article-title":"Cell cultures in drug discovery: an industrial perspective","author":"Ungell","year":"2004"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0520","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1208\/s12248-010-9227-8","article-title":"Application of method suitability for drug permeability classification","volume":"12","author":"Volpe","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0525","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jaut.2009.11.006","article-title":"Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract","volume":"34","author":"Powell","year":"2010","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0530","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fphar.2013.00079","article-title":"Alternative functional in vitro models of human intestinal epithelia","volume":"4","author":"Kauffman","year":"2013","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0535","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0928-0987(95)00007-Z","article-title":"Co-cultures of human intestinal goblet (HT29-H) and absorptive (Caco-2) cells for studies of drug and peptide absorption","volume":"3","author":"Wikman-Larhed","year":"1995","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0540","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1021\/js960110x","article-title":"HT29-MTX\/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans","volume":"85","author":"Walter","year":"1996","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0545","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jnutbio.2008.05.006","article-title":"Characterization of Caco-2 and HT29-MTX cocultures in an in vitro digestion\/cell culture model used to predict iron bioavailability","volume":"20","author":"Mahler","year":"2009","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0550","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ejps.2006.12.006","article-title":"An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells","volume":"30","author":"Rieux","year":"2007","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0555","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1021\/mp400507g","article-title":"Development of an advanced intestinal in vitro triple culture permeability model to study transport of nanoparticles","volume":"11","author":"Schimpel","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0560","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1017\/S0007114510005660","article-title":"Intestinal barrier function and absorption in pigs after weaning: a review","volume":"105","author":"Wijtten","year":"2011","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0565","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/2049-1891-5-15","article-title":"Fiber effects in nutrition and gut health in pigs","volume":"5","author":"Lindberg","year":"2014","journal-title":"J. Anim. Sci. Biotechnol."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0570","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1021\/mp1000795","article-title":"A three-dimensional coculture of enterocytes, monocytes and dendritic cells to model inflamed intestinal mucosa in vitro","volume":"7","author":"Leonard","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0575","doi-asserted-by":"crossref","first-page":"275","DOI":"10.14573\/altex.2012.3.275","article-title":"Screening of budesonide nanoformulations for treatment of inflammatory bowel disease in an inflamed 3D cell-culture model","volume":"29","author":"Leonard","year":"2012","journal-title":"ALTEX"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0580","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1021\/mp400723j","article-title":"A 3-D artificial colon tissue mimic for the evaluation of nanoparticle-based drug delivery system","volume":"11","author":"Huang","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0585","doi-asserted-by":"crossref","first-page":"13708","DOI":"10.1038\/srep13708","article-title":"Robust bioengineered 3D functional human intestinal epithelium","volume":"5","author":"Chen","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0590","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1017\/S0007114512004023","article-title":"In vitro cell and tissue models for studying host-microbe interactions: a review","volume":"109","author":"Bermudez-Brito","year":"2013","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0595","doi-asserted-by":"crossref","first-page":"43e50","DOI":"10.1016\/j.jecm.2013.02.006","article-title":"Human intestinal in vitro organ culture as a model for investigation of bacteria-host interactions","volume":"5","author":"Fang","year":"2013","journal-title":"J. Exp. Clin. Med."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0600","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1177\/1535370214529398","article-title":"Human enteroids as an ex-vivo model of host-pathogen interactions in the gastrointestinal tract","volume":"239","author":"Foulke-Abel","year":"2014","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0605","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1177\/1535370214529388","article-title":"Modeling human gastrointestinal inflammatory diseases using microphysiological culture systems","volume":"239","author":"Hartman","year":"2014","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0610","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tibtech.2014.04.006","article-title":"The promise of organotypic hepatic and gastrointestinal models","volume":"32","author":"Vu","year":"2014","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0615","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.183","article-title":"Ex vivo culture of intestinal crypt organoids as a model system for assessing cell death induction in intestinal epithelial cells and enteropathy","volume":"5","author":"Grabinger","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0620","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature13863","article-title":"Modelling human development and disease in pluripotent stem-cell-derived gastric organoids","volume":"516","author":"McCracken","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0625","doi-asserted-by":"crossref","first-page":"3710836","DOI":"10.1155\/2016\/3710836","article-title":"Three-dimensional gastrointestinal organoid culture in combination with nerves or fibroblasts: a method to characterize the gastrointestinal stem cell niche","volume":"2016","author":"Pastu\u0142a","year":"2016","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0630","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/smll.201401915","article-title":"Biomimicry 3D gastrointestinal spheroid platform for the assessment of toxicity and inflammatory effects of zinc oxide nanoparticles","volume":"11","author":"Chia","year":"2015","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0635","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.tcb.2011.09.005","article-title":"From 3D cell culture to organs-on-chips","volume":"21","author":"Huh","year":"2011","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0640","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s10544-012-9669-0","article-title":"On chip porous polymer membranes for integration of gastrointestinal tract epithelium with microfluidic \u2018body-on-a-chip\u2019 devices","volume":"14","author":"Esch","year":"2012","journal-title":"Biomed. Microdevices"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0645","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1039\/C4LC00371C","article-title":"Body-on-a-chip simulation with gastrointestinal tract and liver tissues suggests that ingested nanoparticles have the potential to cause liver injury","volume":"14","author":"Esch","year":"2014","journal-title":"Lab Chip"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0650","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1039\/c2lc40074j","article-title":"Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow","volume":"12","author":"Kim","year":"2012","journal-title":"Lab Chip"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0655","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1039\/c3ib40126j","article-title":"Gut-on-a-Chip microenvironment induces human intestinal cells to undergo villus differentiation","volume":"5","author":"Kim","year":"2013","journal-title":"Integr. Biol. (Camb)"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0660","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1073\/pnas.1522193112","article-title":"Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip","volume":"113","author":"Kim","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0665","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jconrel.2015.09.052","article-title":"In vitro-in vivo correlation for complex non-oral drug products: where do we stand?","volume":"219","author":"Shen","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0670","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ejps.2013.08.024","article-title":"In vitro models for the prediction of in vivo performance of oral dosage forms","volume":"57","author":"Kostewicz","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0675","first-page":"583","article-title":"A correlative model to predict in vivo AUC for nanosystem drug delivery with release rate-limited absorption","volume":"15","author":"Barzegar-Jalali","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0680","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejps.2013.08.018","article-title":"Animal versus human oral drug bioavailability: do they correlate?","volume":"57","author":"Musther","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0685","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1124\/dmd.109.028829","article-title":"A comparison of pharmacokinetics between humans and monkeys","volume":"38","author":"Akabane","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0690","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/bdd.2510160502","article-title":"Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals","volume":"16","author":"Kararli","year":"1995","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0695","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1021\/mp400086n","article-title":"TPGS emulsified zein nanoparticles enhanced oral bioavailability of daidzin: in vitro characteristics and in vivo performance","volume":"10","author":"Zou","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0700","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1021\/mp300649z","article-title":"Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles","volume":"10","author":"Yuan","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0705","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.colsurfb.2015.02.043","article-title":"Biodegradable polymeric nanoparticles for oral delivery of epirubicin: in vitro, ex vivo, and in vivo investigations","volume":"128","author":"Tariq","year":"2015","journal-title":"Colloids Surf., B"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0710","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1021\/mp400493b","article-title":"Penetratin derivative-based nanocomplexes for enhanced intestinal insulin delivery","volume":"11","author":"Zhu","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0715","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s00204-015-1518-5","article-title":"Progress and future of in vitro models to study translocation of nanoparticles","volume":"89","author":"Braakhuis","year":"2015","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0720","doi-asserted-by":"crossref","first-page":"13803","DOI":"10.1073\/pnas.1305882110","article-title":"Unique insights into the intestinal absorption, transit, and subsequent biodistribution of polymer-derived microspheres","volume":"110","author":"Reineke","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0725","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.nu.08.070188.001553","article-title":"Gastrointestinal absorption of intact proteins","volume":"8","author":"Gardner","year":"1988","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0730","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/wnan.1333","article-title":"Mammalian gastrointestinal tract parameters modulating the integrity, surface properties, and absorption of food-relevant nanomaterials","volume":"7","author":"Bellmann","year":"2015","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0735","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1743-8977-10-9","article-title":"Comparative absorption, distribution, and excretion of titanium dioxide and zinc oxide nanoparticles after repeated oral administration","volume":"10","author":"Cho","year":"2013","journal-title":"Part. Fibre Toxicol."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0740","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12989-015-0085-5","article-title":"Oral absorption of PEG-coated versus uncoated gold nanospheres: does agglomeration matter?","volume":"12","author":"Hinkley","year":"2015","journal-title":"Part. Fibre Toxicol."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0745","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.3762\/bjnano.5.218","article-title":"The gut wall provides an effective barrier against nanoparticle uptake","volume":"5","author":"Sinnecker","year":"2014","journal-title":"Beilstein J. Nanotechnol."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0750","article-title":"Evidence does not support absorption of intact solid lipid nanoparticles via oral delivery","author":"Hu","year":"2016","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0755","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S0264-410X(03)00206-8","article-title":"Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges","volume":"21","author":"Holmgren","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0760","first-page":"507","article-title":"Targeting to intestinal M cells","volume":"189","author":"Jepson","year":"1996","journal-title":"J. Anat."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0765","first-page":"144","article-title":"Uptake and translocation of fluorescent latex particles by rabbit Peyer's patch follicle epithelium: a quantitative model for M cell uptake","volume":"76","author":"Pappo","year":"1989","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0770","first-page":"487","article-title":"Particle uptake and translocation across epithelial membranes","volume":"189","author":"Thomas","year":"1996","journal-title":"J. Anat."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0775","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1096\/fasebj.13.6.611","article-title":"Up-regulation of microsphere transport across the follicle-associated epithelium of Peyer's patch by exposure to Streptococcus pneumoniae R36a","volume":"13","author":"Meynell","year":"1999","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0780","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/path.1700660228","article-title":"An experimental study of the mechanism of action of Vibriod cholerae on the intestinal mucous membrane","volume":"66","author":"De","year":"1953","journal-title":"J. Pathol. Bacteriol."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0785","first-page":"81","article-title":"Absorption of drugs from the rat small intestine","volume":"123","author":"Schanker","year":"1958","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0790","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2567.2004.01964.x","article-title":"Improving M cell mediated transport across mucosal barriers: do certain bacteria hold the keys?","volume":"113","author":"Man","year":"2004","journal-title":"Immunology"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0795","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jconrel.2015.07.033","article-title":"Micro\/nanofabricated platforms for oral drug delivery","volume":"219","author":"Fox","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0800","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2006.04.017","article-title":"Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan\u2013a review","volume":"114","author":"George","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0805","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1021\/bm900985h","article-title":"Nanoparticles incorporated in pH-sensitive hydrogels as amoxicillin delivery for eradication of Helicobacter pylori","volume":"11","author":"Chang","year":"2010","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0810","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1016\/j.biomaterials.2013.02.028","article-title":"Genipin-cross-linked fucose-chitosan\/heparin nanoparticles for the eradication of Helicobacter pylori","volume":"34","author":"Lin","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0815","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2217\/nnm.14.76","article-title":"Berberine-loaded targeted nanoparticles as specific Helicobacter pylori eradication therapy: in vitro and in vivo study","volume":"10","author":"Lin","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0820","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1021\/acs.biomac.5b00907","article-title":"Active targeted nanoparticles for oral administration of gastric cancer therapy","volume":"16","author":"Lin","year":"2015","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0825","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejpb.2015.10.010","article-title":"A strategy for oral chemotherapy via dual pH-sensitive polyelectrolyte complex nanoparticles to achieve gastric survivability, intestinal permeability, hemodynamic stability and intracellular activity","volume":"97","author":"Deng","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0830","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jconrel.2011.01.011","article-title":"Mucoadhesive curcumin nanospheres: biological activity, adhesion to stomach mucosa and release of curcumin into the circulation","volume":"151","author":"Suwannateep","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0835","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.carbpol.2014.03.025","article-title":"Ethyl cellulose nanoparticles: clarithomycin encapsulation and eradication of H. pylori","volume":"109","author":"Pan-In","year":"2014","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0840","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2217\/nnm.13.30","article-title":"Combating Helicobacter pylori infections with mucoadhesive nanoparticles loaded with Garcinia mangostana extract","volume":"9","author":"Pan-in","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0845","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1021\/bm5012618","article-title":"Acrylate-tethering drug carrier: covalently linking carrier to biological surface and application in the treatment of Helicobacter pylori infection","volume":"15","author":"Tachaprutinun","year":"2014","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0850","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1128\/IAI.01000-12","article-title":"Helicobacter pylori infection impairs the mucin production rate and turnover in the murine gastric mucosa","volume":"81","author":"Navabi","year":"2013","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0855","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ijpharm.2015.08.004","article-title":"VB12-coated Gel-Core-SLN containing insulin: another way to improve oral absorption","volume":"493","author":"He","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0860","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.actbio.2015.12.017","article-title":"Vitamin B12 functionalized layer by layer calcium phosphate nanoparticles: a mucoadhesive and pH responsive carrier for improved oral delivery of insulin","volume":"31","author":"Verma","year":"2016","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0865","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijpharm.2014.06.052","article-title":"M-cell targeted polymeric lipid nanoparticles containing a Toll-like receptor agonist to boost oral immunity","volume":"473","author":"Ma","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0870","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.biomaterials.2014.10.038","article-title":"Enhanced transport of nanocage stabilized pure nanodrug across intestinal epithelial barrier mimicking Listeria monocytogenes","volume":"37","author":"Xia","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0875","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10717544.2015.1031295","article-title":"A novel ligand conjugated nanoparticles for oral insulin delivery","volume":"27","author":"Liu","year":"2015","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0880","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijpharm.2016.01.028","article-title":"The transport mechanism of integrin \u03b1v\u03b23 receptor targeting nanoparticles in Caco-2 cells","volume":"500","author":"Xu","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0885","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.biomaterials.2011.10.075","article-title":"Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport","volume":"33","author":"Jin","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0890","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s11095-014-1513-1","article-title":"The glucose-lowering potential of exenatide delivered orally via goblet cell-targeting nanoparticles","volume":"32","author":"Li","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0895","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1021\/mp400685v","article-title":"Mechanism study of cellular uptake and tight junction opening mediated by goblet cell-specific trimethyl chitosan nanoparticles","volume":"11","author":"Zhang","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0900","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1080\/03639040802130061","article-title":"Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery","volume":"34","author":"Muchow","year":"2008","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0905","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.addr.2007.04.009","article-title":"Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles","volume":"59","author":"Date","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0910","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1517\/17425247.2012.666967","article-title":"Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals","volume":"9","author":"Puglia","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0915","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.nano.2015.09.004","article-title":"Nanostructured lipid carriers: promising drug delivery systems for future clinics","volume":"12","author":"Beloqui","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0920","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejps.2010.10.002","article-title":"Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting","volume":"42","author":"Aji","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0925","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.nano.2011.08.016","article-title":"Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats","volume":"8","author":"Zhang","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0930","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijpharm.2015.02.070","article-title":"Development, optimization and evaluation of long chain nanolipid carrier for hepatic delivery of silymarin through lymphatic transport pathway","volume":"485","author":"Chaudhary","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0935","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ijpharm.2014.06.048","article-title":"Design of lipotomes as a novel dual functioning nanocarrier for bioavailability enhancement of lacidipine: in-vitro and in-vivo characterization","volume":"472","author":"ElKasabgy","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0940","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1517\/17425247.2014.915310","article-title":"Solid lipid nanoparticles of diethylcarbamazine citrate for enhanced delivery to the lymphatics: in vitro and in vivo evaluation","volume":"11","author":"Siram","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0945","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/jps.23967","article-title":"Enhancement of oral bioavailability of tripterine through lipid nanospheres: preparation, characterization, and absorption evaluation","volume":"103","author":"Zhang","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0950","first-page":"495","article-title":"Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake","volume":"9","author":"Cho","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0955","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejpb.2013.12.015","article-title":"Lipid nanoparticles for oral delivery of raloxifene: optimization, stability, in vivo evaluation and uptake mechanism","volume":"87","author":"Ravi","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0960","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1158\/0008-5472.CAN-10-3118","article-title":"High plasma levels and effective lymphatic uptake of docetaxel in an orally available nanotransporter formulation","volume":"71","author":"Nassar","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0965","doi-asserted-by":"crossref","first-page":"17498","DOI":"10.1073\/pnas.1313839110","article-title":"Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption","volume":"110","author":"Attili-Qadri","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0970","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jps.23828","article-title":"pH-sensitive nanoparticles of curcumin-celecoxib combination: evaluating drug synergy in ulcerative colitis model","volume":"103","author":"Gugulothu","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0975","first-page":"3789","article-title":"Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy","volume":"9","author":"Naeem","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0980","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.colsurfb.2014.09.026","article-title":"Enzyme\/pH dual sensitive polymeric nanoparticles for targeted drug delivery to the inflamed colon","volume":"123","author":"Naeem","year":"2014","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0985","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jconrel.2014.03.039","article-title":"Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases","volume":"183","author":"Ali","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.016_bb0990","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijpharm.2014.07.009","article-title":"pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease","volume":"473","author":"Beloqui","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb0995","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1053\/j.gastro.2012.06.043","article-title":"An orally administered redox nanoparticle that accumulates in the colonic mucosa and reduces colitis in mice","volume":"143","author":"Vong","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2016.06.016_bb1000","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jconrel.2015.05.275","article-title":"Specific accumulation of orally administered redox nanotherapeutics in the inflamed colon reducing inflammation with dose-response efficacy","volume":"210","author":"Vong","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.06.016_bb1005","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s00535-013-0836-8","article-title":"Oral nanotherapeutics: effect of redox nanoparticle on microflora in mice with dextran sodium sulfate-induced colitis","volume":"49","author":"Vong","year":"2014","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2016.06.016_bb1010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.biomaterials.2015.03.037","article-title":"Development of an oral nanotherapeutics using redox nanoparticles for treatment of colitis-associated colon cancer","volume":"55","author":"Vong","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2016.06.016_bb1015","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.5b00676","article-title":"Combination treatment of murine colon cancer with doxorubicin and redox nanoparticles","author":"Vong","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb1020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijpharm.2012.07.017","article-title":"Drug delivery to inflamed colon by nanoparticles: comparison of different strategies","volume":"440","author":"Coco","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.06.016_bb1025","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/gastro\/gou070","article-title":"Biological therapy for ulcerative colitis","volume":"3","author":"Arora","year":"2015","journal-title":"Gastroenterol. Rep."},{"key":"10.1016\/j.jconrel.2016.06.016_bb1030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2014.04.046","article-title":"Merlin, Fab'-bearing siRNA TNF\u03b1-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis","volume":"186","author":"Laroui","year":"2014","journal-title":"J. Control. Release"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916303819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916303819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T15:22:35Z","timestamp":1718637755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365916303819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":204,"alternative-id":["S0168365916303819"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.06.016","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoparticles for oral delivery: Design, evaluation and state-of-the-art","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}